These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29147262)

  • 21. Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.
    Heymann JJ; Bulman WA; Maxfield RA; Powell CA; Halmos B; Sonett J; Beaubier NT; Crapanzano JP; Mansukhani MM; Saqi A
    Cytojournal; 2014; 11():12. PubMed ID: 24987443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
    Wang H; Agulnik J; Kasymjanova G; Wang A; Jiménez P; Cohen V; Small D; Pepe C; Sakr L; Fiset PO; Auger M; Camilleri-Broet S; Alam El Din M; Chong G; van Kempen L; Spatz A
    Ann Oncol; 2018 Jun; 29(6):1417-1422. PubMed ID: 29659668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
    Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
    Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.
    Giannini R; Lupi C; Sensi E; Alì G; Proietti A; Boldrini L; Servadio A; Giordano M; Macerola E; Bruno R; Borrelli N; Chella A; Melfi F; Lucchi M; Ribechini A; Vasile E; Cappuzzo F; Mussi A; Fontanini G
    Oncol Rep; 2016 Aug; 36(2):1166-72. PubMed ID: 27373829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: Need for better cell block processing.
    Harada S; Agosto-Arroyo E; Levesque JA; Alston E; Janowski KM; Coshatt GM; Eltoum IA
    Cancer Cytopathol; 2015 Aug; 123(8):480-7. PubMed ID: 25955105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
    Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation analysis by next-generation sequencing in endoscopic ultrasound-guided sampling for solid liver masses.
    Choi HJ; Moon JH; Kim HK; Lee YN; Lee TH; Cha SW; Cho YD; Park SH
    J Gastroenterol Hepatol; 2017 Jan; 32(1):154-162. PubMed ID: 27118240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytology smears as diagnostic material for EGFR gene testing in non-small cell lung cancer.
    Powrózek T; Krawczyk P; Pankowski J; Reszka K; Jakubiak M; Obrochta A; Wojas-Krawczyk K; Buczkowski J; Milanowski J
    Tumori; 2015 Nov; 101(6):e151-3. PubMed ID: 26108238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle.
    Cheung YC; Chang JW; Hsieh JJ; Lin G; Tsai YH
    Lung Cancer; 2010 Feb; 67(2):166-9. PubMed ID: 19450892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma.
    Betz BL; Roh MH; Weigelin HC; Placido JB; Schmidt LA; Farmen S; Arenberg DA; Kalemkerian GP; Knoepp SM
    Am J Clin Pathol; 2011 Oct; 136(4):564-71. PubMed ID: 21917678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
    Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
    Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
    Hatogai K; Fujii S; Kojima T; Daiko H; Doi T; Ohtsu A; Ochiai A; Takiguchi Y; Yoshino T
    BMC Cancer; 2017 Jan; 17(1):36. PubMed ID: 28068934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
    Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.